IOVANCE BIOTHERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $263.5 | $164.1 | $1.2 | — | — |
| Operating income | -$403.4 | -$395.3 | -$460.6 | -$398.9 | -$342.7 |
| Net income | -$391.0 | -$372.2 | -$444.0 | -$395.9 | -$342.3 |
| Cash Flow Statement | |||||
| Free cash flow | -$336.2 | -$364.0 | -$384.1 | -$313.2 | -$265.5 |
Shares outstanding 453.0M · Free float 84.6%
Annual filing data through FY ended December 31, 2025; float as of September 10, 2026.